Department of Urology, Mayo Clinic, Jacksonville, Florida, USA.
Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, Florida, USA.
J Endourol. 2021 Jun;35(6):808-813. doi: 10.1089/end.2020.0801. Epub 2020 Nov 26.
To evaluate the association between the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) preoperatively with changes in estimated glomerular filtration rate (eGFR) after robotic-assisted partial nephrectomy (RAPN). Patients undergoing RAPN at our institution from February 2008 through April 2019 were evaluated. ACEIs/ARBs were held on the morning of the surgery and resumed on postoperative day number one in all patients. Associations of ACEIs/ARBs use with postoperative eGFR were explored by using a linear mixed-effects regression model with random patient-specific intercepts. We included eGFR measurements at the following time points: preoperatively, postoperative day 1 (POD1), 1 month postoperative, 6 months postoperative, and 12 months postoperative. -Values <0.05 were considered statistically significant. One hundred and seventy-one (44.0%) of 389 patients were on ACEIs/ARBs therapy preoperatively. The ACEIs/ARBs patients were older and had higher rates of comorbidities, including diabetes mellitus. The ACEIs/ARBs patients tended to have lower preoperative eGFR (mean ± standard deviation, 70.4 ± 17.5 78.0 ± 19.2 mL/minute/1.73 m; < 0.001). However, this was not significant after adjustment for potentially confounding variables (mean difference, -1.7 mL/minute/1.73 m; 95% confidence interval, -6.4 to 3.1 mL/minute/1.73 m; = 0.48). There was no evidence of an association of ACEIs/ARBs use with postoperative renal function after adjustment for potentially confounding variables (adjusted mean difference in change in eGFR from baseline was -1.1, -1.2, -0.3, and -1.2 mL/minute/1.73 m at POD1, 1, 6, and 12 months, respectively; all ≥ 0.51). Continuation of ACEIs and ARBs throughout the perioperative period is not associated with change in post-RAPN eGFR.
评估血管紧张素转换酶抑制剂 (ACEI) 和血管紧张素受体阻滞剂 (ARB) 在机器人辅助部分肾切除术 (RAPN) 后估算肾小球滤过率 (eGFR) 变化中的术前使用与变化之间的关系。 评估了 2008 年 2 月至 2019 年 4 月期间在我院接受 RAPN 的患者。所有患者均在手术当天早上停用 ACEI/ARB,并在术后第 1 天恢复使用。使用具有随机患者特定截距的线性混合效应回归模型探讨 ACEI/ARB 使用与术后 eGFR 的相关性。我们包括以下时间点的 eGFR 测量值:术前、术后第 1 天 (POD1)、术后 1 个月、术后 6 个月和术后 12 个月。-值<0.05 被认为具有统计学意义。 389 例患者中有 171 例 (44.0%) 术前接受 ACEI/ARB 治疗。ACEI/ARB 患者年龄较大,合并症发生率较高,包括糖尿病。ACEI/ARB 患者的术前 eGFR 较低(平均值±标准差,70.4±17.5 与 78.0±19.2 毫升/分钟/1.73 米;<0.001)。然而,在调整了潜在混杂变量后,这并不显著(平均差异,-1.7 毫升/分钟/1.73 米;95%置信区间,-6.4 至 3.1 毫升/分钟/1.73 米;=0.48)。在调整了潜在混杂变量后,ACEI/ARB 使用与术后肾功能之间没有关联(从基线到术后第 1 天、第 1 个月、第 6 个月和第 12 个月的 eGFR 变化的调整平均差异分别为-1.1、-1.2、-0.3 和-1.2 毫升/分钟/1.73 米;所有差异均≥0.51)。整个围手术期继续使用 ACEI 和 ARB 与 RAPN 后 eGFR 的变化无关。